PAGE Therapeutics is developing anti-metastatic compounds that target circulating tumor cell clusters (CTC clusters) to prevent the formation of metastases in solid tumor cancer patients. Their approach has demonstrated survival benefits in preclinical models and is currently being validated in a proof-of-concept clinical trial for breast cancer.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastasis, the spread of cancer from a primary tumor to distant sites, is responsible for the majority of cancer-related deaths. Circulating tumor cell clusters (CTC clusters) are multicellular aggregates of cancer cells that are highly efficient at initiating the metastatic process. Currently, there are no approved therapies specifically targeting CTC clusters to prevent metastasis.
Solution
PAGE Therapeutics is developing a novel class of anti-metastatic compounds designed to dissolve circulating tumor cell clusters (CTC clusters) and thereby prevent the formation of metastases. Their platform identifies and develops new chemical entities (NCEs) with high cluster-dissolution activity. Preclinical studies have demonstrated that dissolution of CTC clusters with PAGE Therapeutics' compounds can shut down metastasis and improve survival in animal models. A proof-of-concept clinical trial in breast cancer patients is underway to validate the CTC cluster dissolution activity and anti-metastatic potential of their lead compound. This approach aims to address a critical unmet need by directly targeting the root cause of metastatic spread.
Target Audience
The primary target audience includes solid tumor cancer patients at risk of developing metastasis, as well as oncologists and researchers focused on developing new anti-metastatic therapies.
Features
- Compounds designed to disrupt the adhesion molecules holding CTC clusters together, leading to their disaggregation.
- Demonstrated dissolution of CTC clusters in preclinical models.
- Survival benefit shown in mouse models of metastasis.
- Proof-of-concept clinical trial in breast cancer patients to assess CTC cluster dissolution.
- New chemical entities (NCEs) with optimized cluster-dissolution activity.